Business
Carlsmed is a commercial-stage medical technology company developing AI-enabled personalized spine surgery solutions through its aprevo Technology Platform.
Carlsmed ended FY2025 with stronger equity after its IPO, but the loss and FCF deficit widened and the local extract had no revenue row.
The read at a glance✓ Audited against SEC data
- Business mix — Personalized spine devicesNote
- Revenue — No revenue rowNote
- Net income — -$29.6M, worseWatch
- FCF — -$29.6M, worseWatch
- Equity — $98.9M vs deficitOK
- Insiders — $48.0M purchases / 1 saleOK
- Accounting — Forensic screen unavailableNote
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-06-03
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CARLSMED, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.